CloneID: HuMBC1
Antigen Long Description: The anti-PTHrP antibody was prepared by immunizing mice with synthetic bovine thyroglobulin-conjugated PTHrP (aa 1-34) and generating the hybridoma cell line #23-57-137-1. The CRD regions of the variable region of the heavy chain was grafted onto the human framework regions of the human antibody S31679, and for the light chain FR1, FR2 and FR3 weregrafted to that of HSU03868 and FR4 of the mouse antibody wasgrafted to that of S31679.
Origin Pub PMID: 15517871
Buffer Composition: PBS only.
Specificity Statement: HuMBC1 binds to human PTHrPat an epitope between residues 20 and 30(KD ~ 0.2 nM), a site closely overlapping with the GPCR parathyroid hormone receptor 1 (PTH1R) binding site. The antibody does not bind to PTH at concentrations of 10ug/ml. PTHrP is known to be a causative factor of humoural hypercalcemia of malignancy (HHM), which is frequently found at advanced stages of cancer. The protein binds to PTHR1, which is expressed on the surface of cells of the osteoblast lineage and of the kidney tubule; this interaction actively promotes bone resorption, in a manner identical to that of PTH.
Application Notes (Clone): HuMBC1 can almost completely blocks the PTHrP-induced cAMP production in rat osteosarcoma cells that expressed PTHR1, even in the presence of 2 g/mL PTHrP(1-34) – the neutralizing activity in the humanized antibody is equilavent to that of the murine antibody from which it is derived (#23-57-137-1). The humanized antibody is also effective in reducing the blood ionized calcium levels of hypercalcemic mice bearing the PAN-7-JCK human pancreatic cancer xenograft or the LC-6-JCK human lung cancer xenograft that secreted PTHrP. PTH binding and activity is not neutralized by this antibody. The antibody can also be used to detect the presence of and binding of PTHrP by EILSA.